[Anti-interferon antibody in chronic hepatitis C].
We studied anti-interferon (IFN) antibody in serial serum samples, obtained from 34 patients with chronic hepatitis C treated with IFN (HLBI, recombinant IFN-alpha 2a or-2b, HuIFN-beta). Anti-IFN antibody was measured by Western blotting, Anti-IFN antibody was detected in nine (8.1%) of the 111 samples. Two patients treated with recombinant IFN-alpha 2a developed neutralizing anti-IFN antibody, with the development of clinical resistance to IFN therapy, while none of 32 patients treated with either HLBI, recombinant IFN-alpha 2b or HuIFN-beta developed anti-IFN antibody. Anti-IFN antibody was developed in one patients one month after IFN. It is believed that Western blotting, used in this study, is a useful method to evaluate the incidence and clinical significance of anti-IFN antibody.
Arai
K
K
Department of Internal Medicine, Akashi Municipal Hospital.
Shindo
M
M
Okuno
T
T
D000328:Adult; D000906:Antibodies / Q000032:analysis*; D002908:Chronic Disease; D005260:Female; D006526:Hepatitis C / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007370:Interferon Type I / Q000276:immunology; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000276:immunology; D007372:Interferons / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
D000906:Antibodies; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D007372:Interferons